AU2020394255A1 - Long-acting GDF15 fusion protein and pharmaceutical composition comprising same - Google Patents

Long-acting GDF15 fusion protein and pharmaceutical composition comprising same Download PDF

Info

Publication number
AU2020394255A1
AU2020394255A1 AU2020394255A AU2020394255A AU2020394255A1 AU 2020394255 A1 AU2020394255 A1 AU 2020394255A1 AU 2020394255 A AU2020394255 A AU 2020394255A AU 2020394255 A AU2020394255 A AU 2020394255A AU 2020394255 A1 AU2020394255 A1 AU 2020394255A1
Authority
AU
Australia
Prior art keywords
gdf15
amino acid
seq
fusion protein
acting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020394255A
Other languages
English (en)
Inventor
Hyun Ho Choi
Wonee Chong
Mi Kyeong Ju
Junhwan Kim
Sukyung KIM
Won Tae Kim
Youn Woo Lee
Seyoung LIM
Young Bong Park
Bo Ra SIM
Ji Eun Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of AU2020394255A1 publication Critical patent/AU2020394255A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2020394255A 2019-11-26 2020-11-25 Long-acting GDF15 fusion protein and pharmaceutical composition comprising same Pending AU2020394255A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2019-0153680 2019-11-26
KR20190153680 2019-11-26
PCT/KR2020/016842 WO2021107603A2 (en) 2019-11-26 2020-11-25 Long-acting gdf15 fusion protein and pharmaceutical composition comprising same

Publications (1)

Publication Number Publication Date
AU2020394255A1 true AU2020394255A1 (en) 2022-06-09

Family

ID=76130664

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020394255A Pending AU2020394255A1 (en) 2019-11-26 2020-11-25 Long-acting GDF15 fusion protein and pharmaceutical composition comprising same

Country Status (11)

Country Link
US (1) US20230002460A1 (https=)
EP (1) EP4065597A4 (https=)
JP (1) JP2023503472A (https=)
KR (1) KR20210065057A (https=)
CN (1) CN114729020A (https=)
AU (1) AU2020394255A1 (https=)
BR (1) BR112022010227A2 (https=)
CA (1) CA3161302A1 (https=)
MX (1) MX2022006173A (https=)
WO (1) WO2021107603A2 (https=)
ZA (1) ZA202204624B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117750968A (zh) * 2021-05-21 2024-03-22 株式会社柳韩洋行 用于预防或治疗非酒精性脂肪性肝病或非酒精性脂肪性肝炎的包括生长分化因子-15变体的组合物
CA3219645A1 (en) * 2021-05-21 2022-11-24 Yuhan Corporation Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist
US20240391971A1 (en) * 2021-08-24 2024-11-28 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and uses thereof
CN120530128A (zh) * 2022-11-18 2025-08-22 株式会社柳韩洋行 双功能蛋白及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
EP2441466B1 (en) 2004-04-13 2014-07-23 St Vincent's Hospital Sydney Limited MIC-1 inhibiting agent
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
EP3683228A3 (en) * 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
US9161966B2 (en) * 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
KR101993714B1 (ko) * 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US9862752B2 (en) * 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
RU2017101436A (ru) * 2014-06-24 2018-07-24 Ново Нордиск А/С Mic-1 слитные белки и их применение
AU2015296640B2 (en) * 2014-07-30 2020-05-21 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US10603359B2 (en) * 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
EP3701969A1 (en) * 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
KR101727506B1 (ko) * 2016-07-14 2017-05-04 충남대학교 산학협력단 Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
CN114729020A (zh) 2022-07-08
EP4065597A4 (en) 2024-01-24
EP4065597A2 (en) 2022-10-05
CA3161302A1 (en) 2021-06-03
BR112022010227A2 (pt) 2022-09-13
WO2021107603A2 (en) 2021-06-03
US20230002460A1 (en) 2023-01-05
KR20210065057A (ko) 2021-06-03
WO2021107603A3 (en) 2021-07-15
JP2023503472A (ja) 2023-01-30
MX2022006173A (es) 2022-06-14
ZA202204624B (en) 2023-11-29

Similar Documents

Publication Publication Date Title
WO2021107603A2 (en) Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
WO2017074117A1 (en) Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same
WO2015183054A1 (en) Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist
WO2014133324A1 (ko) 신규한 인슐린 아날로그 및 이의 용도
WO2016114633A1 (en) Long-acting fgf21 fusion proteins and pharmaceutical composition comprising the same
WO2020022776A1 (en) Fusion protein comprising thyrotropin receptor variants and use thereof
WO2020231199A1 (ko) 신규 변형 면역글로불린 fc 융합단백질 및 그의 용도
WO2019135668A1 (ko) Ige fc 수용체의 알파 서브유닛의 세포외 도메인, 이를 포함하는 약학적 조성물 및 이의 제조방법
WO2020050626A1 (ko) O-글리코실화 가능한 폴리펩타이드 영역을 포함하는 융합 폴리펩타이드
WO2016006963A1 (en) Insulin analogue
WO2022245179A1 (en) Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist
WO2022005174A1 (ko) 항-lag-3 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
WO2019135666A1 (ko) Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 약학적 조성물
WO2021096275A1 (ko) 변형된 인터루킨-7 및 tgf 베타 수용체 ii를 포함하는 융합단백질 및 이의 용도
TWI889865B (zh) 包含類升糖素胜肽-1及介白素-1受體拮抗物的融合蛋白及其用途
WO2017188653A1 (en) Fusion protein comprising ccl3 variant and use thereof cross-reference to related applications
WO2022245183A1 (en) Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
WO2023003331A1 (en) Sirp-alpha variants and use thereof
RU2836280C1 (ru) Слитый белок gdf15 длительного действия и содержащая его фармацевтическая композиция
WO2018004294A2 (ko) 인간 성장호르몬 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물
WO2022010273A1 (ko) 보체 경로 억제제를 포함하는 융합단백질 및 이의 용도
WO2023158027A1 (en) A fusion protein comprising an antigen binding domain and a cytokine trimer domain
WO2017052324A1 (en) Method of producing immunoglobulin fc region including initial methionine residue
HK40073215A (en) Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
JP2025539794A (ja) 二重機能タンパク質およびその使用